Navigation Links
Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
Date:1/31/2008

- Laureate to Manufacture ARIUS' Product Candidate Trop-2 Signal

Transduction Antibody -

PRINCETON, N.J., Jan. 31 /PRNewswire/ -- Laureate Pharma, Inc., a full- service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with ARIUS Research, Inc., a biotechnology company focused on discovering and developing the next wave of antibody therapeutics to treat cancer and other diseases, for its Trop-2 Signal Transduction Antibody Program. Laureate will produce ARIUS' IgG1 humanized antibody under the agreement. ARIUS' Trop-2 antibody program targets a novel marker that has been linked in the scientific literature to aggressive cancers including pancreatic, colon, breast and prostate cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

"Our specialized experience in the manufacture of monoclonal antibodies makes us an ideal partner to support ARIUS and the manufacturing of their Trop-2 Signal Transduction Antibody," said Robert J. Broeze, Ph.D., President & CEO of Laureate. "As with all of our Life Science client companies, we will work closely with the ARIUS team to help them achieve their manufacturing objectives."

"The initiation of manufacturing for our second drug candidate demonstrates our ability to execute on our milestones and move multiple candidates from the ARIUS pipeline of drug candidates forward," said Dr. David S. Young, President and Chief Executive Officer of ARIUS. "Laureate Pharma has a track record of expertise in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials and will provide us with a supply of our Trop-2 targeting drug necessary to begin our preclinical studies in the first quarter of 2008 in preparation for human clinical trials."

ARIUS' Trop-2 Signal Transduction Antibody Program has produced the only unconjugated antibody currently in development targeting this novel marker. Trop-2 is a protein expressed on the cell-surface and found in many cancer indications including pancreatic, colon, breast and prostate cancer. The target is thought to be a key part of the expansive MAPK pathway. Of more than 900 abstracts considered for oral presentation at the October 2007 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, the abstract on Trop-2 was one of 12 selected. The Trop-2 Signal Transduction Program was generated using ARIUS' proprietary FunctionFIRST(TM) technology, which selects antibodies based on their ability to kill cancer cells.

About Laureate Pharma, Inc.

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a partner company of Safeguard Scientifics, Inc. (NYSE: SFE), which provides growth capital for entrepreneurial and innovative technology and life sciences companies through expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. (http://www.safeguard.com) For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM) that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
2. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... Luxembourg (PRWEB) , ... April 27, 2017 , ... Mitotech ... study in Leber’s Hereditary Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic ... efficacy of SkQ1 eye drops in a group of 20 patients carrying 11778, 14484 ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... and a name change to Fluence Analytics. , Fluence Analytics provides ... polymer and biopharmaceutical manufacturing processes and R&D applications. The company’s patented technologies ...
(Date:4/26/2017)... ... April 26, 2017 , ... Looking for ... and cooking events company, offers one-of-a-kind gifts, ranging from gourmet cooking experiences to ... cuisine, and guests leave inspired with new cooking tips and techniques, thanks to ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... and North America this May on the following dates: , ... H. Taylor, Chairman of the Learning and Performance Institute will be the ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
Breaking Biology News(10 mins):